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The type of immune response induced by tuberculosis (Th1 or Th2) and its correlation with the clinical outcome is
unclear. We studied 13 patients with active tuberculosis (TBC). The peripheral blood mononuclear cells producing
IFN-gamma (PBMC-IG) were measured by enzyme-linked immunospot (ELISPOT) technique. The control group
had ten healthy individuals vaccinated against tuberculosis. We collected blood samples of each patient in two
moments: a) in the hospital admission without treatment (TBC1); b) after seven to 20 days of treatment (TBC2).
The comparison of the spots forming units of PBMC-IG between TBC group and controls showed that there was a
significant difference between TBC1 and control group (p < 0.001) and between TBC2 and control group (p < 0.005),
but there was no difference between TBC1 and TBC2 (p > 0.05). A positive correlation was found between PBMC-IG
and hemoglobin value, as well as between PBMC-IG and weight loss. There was no correlation between PBMC-IG
and other variables [age, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)]. We conclude that
tuberculosis activates Th1 immune response due to increase of PBMC producing IFN-gamma. There was no difference
between the first sample (TBC1) and the second sample (TBC2) of PBMC-IG. This result can have occurred due to
treatment influence, or can indicate that the immune response reachs a plateau. The positive correlation among
PBMC-IG and both hemoglobin level and weight loss indicates that may exist a link between patient’s clinical
status and the immune response intensity.
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The characterization of T cell responses by measurement
of cytokine secretion by ELISPOT assay has become widely
used, mainly in the vaccine production, cancer immunotherapy
[1,2], and in the immune response evaluation against infectious
agents [1,3,4].
The role of cytokines produced by Th1/Th2 lymphocytes
is complex due to the action of TNF-alpha, IL-12, IFN-gamma
(pro-inflammatory cytokines) and IL-4, IL-10 and TGF-beta
(anti-inflammatory cytokines). Th1 lymphocytes produce pro-
inflammatory cytokines while Th2 lymphocytes produce anti-
inflammatory cytokines. Normally, the Th1 immune response
is correlated with tissue injury. In this way, the clinical form of
infectious diseases, as well as the cell death intensity will be
determined by the predominant immune response, Th1 or Th2.
In patients with tuberculosis (TBC) and PPD skin test positive
the predominant immune response may be Th1, although there
are few studies in this field.
The cellular immune response is essential for tuberculosis
resistance, mainly through cytokines production such as IL-
12, IL-18, IFN-gamma, IL-2 and TNF-alpha. The CD8+ T cells
perform cytotoxic action mainly through major
histocompatibility complex (MHC) class I molecules in
association with CD1d molecules presenting glycolipids
antigens to T lymphocyte cells [5]. Cytotoxic T lymphocyte
cells (CTLs) may have a protective role in TBC disease by
several mechanisms: 1) Producing potent antibacterial
cytokines such as IFN-gamma and TNF-alpha; 2) Presenting
M. tuberculosis antigens associated to HLA-I complex; 3)
Inducing apoptosis in infected cells [6,7].
The enzyme-linked immunosorbent spot (ELISPOT)
technique has been used in a crescent form for
quantification of peripheral blood mononuclear cells
(PBMC) producing specific cytokines in patients with
infectious diseases [2,8,9]. There are several advantages
of the ELISPOT assay for use in field settings: it is relatively
easy to perform, does not require expensive
instrumentation, and has the potential for high throughput
screening. Through ELISPOT technique, several authors
reported that the quantification of peripheral blood
mononuclear cells producing IFN-gamma (PBMC-IG)
presented cytotoxicity in response to influenzae peptide
[1,2,9]. Several studies have shown that ELISPOT is more
sensitive for detection of cytokines than ELISA technique
[10-12]. However, there are not studies about PBMC-IG in
patients with tuberculosis.
The discovery of the predominance of a specific cytokine
in the inflammatory microenvironment, as well as in the
peripheral blood, may help to understand the evolution of an
infectious agent in the organism. The CD8+ T cells perform
cytotoxic action mainly through major histocompatibility
complex (MHC) class I molecules in association with CD1d
molecules presenting glycolipids antigens to T lymphocyte
cells [5].
In this study we quantified the PBMC-IG in patients with
active tuberculosis employing the ELISPOT technique. Our
results indicate that tuberculosis activates the Th1 immune
response, and also that there is a positive correlation between
PBMC-IG and some clinical and laboratory variables.
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Material and Methods
Patients Selection
Thirteen patients with active tuberculosis were selected
from Infectious Diseases Clinic and Internal Medicine Clinic
of the Clinics Hospital, School of Medicine, University of São
Paulo. The control group had ten healthy individuals
vaccinated against tuberculosis. Informed consent was
obtained from each patient and the protocol for the research
project was approved by the ethics committee of the
institution.
We excluded patients with HIV test (ELISA) positive, and
patients with immunodeficient diseases. Sera of patients and
control group were obtained under sterile conditions and
disposed in tubes containing sodium heparin (0.1 mg/mL).
The maximum volume of the sample collected from each patient
was 20 mL. We collected blood samples of each patient in two
moments: TBC1 = in admission without treatment; TBC2 =
after seven to 20 days under treatment.
Peripheral Blood Mononuclear Cells Isolation
The PBMC isolation followed the protocol based in other
studies [8,9] as follows: PBMC were isolated by centrifugation
gradient with Ficoll-Paque Plus (Amersham). The cells were
washed with saline solution and resuspended in Iscove’s B
medium (Sigma) with 4 mM of l-glutamine (v/v), 100 U/L of
penicillin, 100 U/L of streptomycin, enriched with 10% of
human AB serum pool (Cultilab), and stored in fetal bovine
serum containing DMSO 10% in liquid nitrogen. The freezing
technique was efficient, producing similar replies to fresh cells
[13]. The isolated PBMC were incubated overnight in Iscove’s
medium containing fetal bovine serum (10%) before ELISPOT
assay.
The cells were counted in Neubauer chamber and disposed
in a concentration of 1 x 104 cells/mL in Iscove’s medium,
containing fetal bovine serum (10%).
ELISPOT Assay
We added 100 mL of each sample (with 5 x 104 cells) of ten
controls and 13 tuberculosis patients in a 96-well PVDF plate
coated with a specific IFN-gamma antibody. The plate was
incubated at 37°C in a CO2 incubator for 48 h. The contents of
the plate were discarded and the plate was thoroughly washed
with 300 µL/well of 1x wash buffer, taking care to not damage
the membrane. This procedure was repeated for a total of six
washes. After washing, the plate was turned upside down
and blotted onto paper towels. We added 50 µL of IFN-gamma-
detection antibody to each well. The plate was covered and
incubated for 1 h at room temperature. After this, it was washed
six times again. We added 100 µL of diluted streptavidin-AP
conjugate to each well. The plate was covered and incubated
for one hour at room temperature, and it was washed six times
again. Then, we added 100 µL of NBT/BCIP substrate solution
to each well. The color reaction was developed at room
temperature, in the dark, for 3-15 minutes. The contents of the
plate were discarded and it was rinsed with ultra pure water to
stop the reaction. The plate was turned upside down, allowing
the membrane to completely dry prior to analysis. The spot-
forming units (SFU) had been counted by using a dissection
microscope (Quimis).
Statistical Analysis
The variables were tested about Gaussian distribution
through Kolmogorov-Smirnov test (K-S) and Shapiro-Wilks
test, and they were classified as parametric or nonparametric.
The values were expressed as mean and standard deviation
for parametric variables. In this group, we realized Student’s t
test unpaired for two groups comparison, and ANOVA test
followed by Newman-Keuls post-test for comparison of more
than two groups. Otherwise, the values were expressed as
median and sample variability is reported as 25% and 75%
percentiles for nonparametric variables. In this group we
utilized the Kruskal-Wallis multiple comparisons test with
Muller-Dunn post-test when comparing two or more unpaired
groups and the unpaired Mann-Whitney test was used to
compare two distinct groups.
The Pearson’s correlation was made when indicated. An
alpha risk equal or lower than 5% (p ≤ 0.05) was considered
statistically significant.
Results
The data of patients’ clinical status were: 9/13 had weight
loss ranging between three and 26 Kg; 8/13 had fever; 8/13
had cough without sputum; 6/13 had night sweats; 2/13 had
cough with sputum. The diagnostic imaging tests showed:
10/13 had chest X-ray abnormal, of which 1/13 developed
pulmonary cavitations, and 3/13 had signs of lymph nodes
necrosis. The tuberculosis group had four women and nine
men, and the control group had seven women and three men.
The tuberculosis patients had the following clinical forms:
9 = pulmonary, 1 = pleural, 1 = lymphatic + splenic, and 2 =
lymphatic. In relation to the clinical therapy, 10/13 did not have
received anti-tuberculosis drugs at the time of blood sampling,
and 3/13 were using therapeutic scheme with isoniazid, rifampin
and pyrazinamide for less than one week. The PPD skin test
was positive in 4/13. The C-reactive protein was high in 6/13.
The acid fast bacilli in sputum were positive in 11/13.
SFU counting of PBMC-IG of control group is shown in
Table 1, and the SFU counting of tuberculosis group is shown
in Table 2 (Figure 1). The numbers are concerning to spots
number by 1 x 104 PBMC. The comparison of the spots
counting between PBMC-IG and the control group are shown
in Table 3. There was a significant difference of PBMC-IG
counting between TBC1 (first sample) and control group (p <
0.001) and between TBC2 (second sample) and control group
(p < 0.05), but there was no difference between TBC1 and
TBC2 (p > 0.05).
The values (mean and standard deviation) of TBC1 and
TBC2, age, weight loss, hemoglobin, erythrocyte
sedimentation rate (ESR) and C-reactive protein (CRP) are
shown in Table 4. A positive correlation was found between
Measurement of PBMC-IG in Tuberculosis
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Figure 1. Comparison of spots obtained in control and TBC
patient groups.
PBMC-IG and hemoglobin value (Pearson correlation = 0.714;
p = 0.031; n = 9), as well as between PBMC-IG and weight loss
(Pearson correlation = 0.702; p = 0.05; n = 8) degree. There
was no correlation between PBMC-IG and other variables.
Discussion
The results showed that ELISPOT method used here was
efficient for measurement of PBMC-IG in patients with active
tuberculosis. We verified that patients with active tuberculosis
produce significantly higher PBMC-IG in relation to control
group. These results suggest that tuberculosis activates Th1
immune response due to increase of PBMC-IG. IFN-gamma is
a product mainly of natural killer cells (NK), activates T cells,
and has an important role in host defense against
mycobacteria. IFN-gamma modulates the macrophages
activation, increases MHC class II molecules expression and
antigen presentation, and also increases differentiation of
lymphocyte populations [14]. This cytokine has been
measured ex vivo in serum [15], bronchoalveolar lavage fluids
[16] and pleural effusions of TBC patients [17]. Out of seven
studies using ELISPOT, for found that TBC patients produce
more IFN-gamma than controls [18-21], one found that they
produce less [22], and two found no difference [23,24].
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Table 1. Count of PBMC-IG spots of control group
Patients Count of PBMC-IG
1 6
2 2
3 1
4 1
5 3
6 2
7 0
8 2
9 1
10 0
Table 2. Count of PBMC-IG of tuberculosis patients
Table 3. Comparison of PBMC-IG counts among TBC1, TBC2
and control group in patients with tuberculosis
Table 4. Values of mean and standard-deviation of PBMC-IG
counts for TBC1, TBC2, clinical and laboratory variables in
patients with tuberculosis
Patients TBC1* TBC2
1 5 0
2 26 10
3 23 9
4 16 21
5 27 25
6 21 18
7 3 -
8 23 -
9 30 24
10 45 -
11 11 12
12 12 21
13 65 13
       Note: * = first sample; ** = second sample.
Control TBC1 TBC2
Mean 1.80 23.62** 15.30 **
Standard-Deviation 1.75 16.73 7.89
Standard-Error 0.55 4.64 2.50
Note: We used the ANOVA one-way test. ** p = 0.0004. Statistical
difference among groups (Newman-Keuls post-test): Control
versus TBC1 = p < 0.001; Control versus TBC2 = p < 0.05; TBC2
versus TBC1 = p > 0.05 (not significant).
Patients (N) Mean Standard-deviation
TBC1 13 23.62 16.731
TBC2 10 15.30 7.889
Age 13 40.54 16.184
Weight loss 8 8.13 7.936
Hemoglobin 12 12.833 1.8763
ESR 11 46.64 36.694
CRP 7 78.537 65.4619
CONTROL GROUP
(Control number 7)
TBC GROUP
(Patient number 9)
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Therefore, in order to establish definitive conclusions about
these discrepant results, more studies should be done.
In patients with active tuberculosis, the PBMC-IG count
in second sample (TBC2) was lesser than PBMC-IG count in
first sample (TBC1), but without statistical difference. TBC2
determination was made within seven to 20 days of the
beginning of anti-tuberculosis treatment. In the same way,
Bekker et al. [25] showed that the serum IFN-gamma levels
decreased in patients with TBC after beginning of therapeutic.
Hirsch et al. [26] reported that IFN-gamma production was
lower at the TBC diagnosis, and this phenomenon remains for
12 months. The authors suggested that TBC can induce a
lesser response of T lymphocytes during and after infection.
We speculate that the stability of PBMC-IG values between
TBC1 and TBC2 can have occurred due to treatment influence,
and to the consequent decrease of the bacterial load in each
case. Another possibility is that the immune response reaches
a plateau in normal conditions, or it suffers inhibition for still
unknown mechanism.
In the analysis of the correlation between PBMC-IG levels
and clinical and laboratory variables, we found a positive
correlation among PBMC-IG and hemoglobin and weight loss.
This result indicates that may be a link between patient’s clinical
status and the immune response intensity. We may consider
that greater weight loss indicates higher bacterial load. In
relation to hemoglobin level, it is possible that a patient with
higher hemoglobin is in better clinical condition, and its immune
response will be better too. The correlations between PBMC-
IG and clinical and laboratory variables may indicate that the
immune response against tuberculosis are not “neck or
nothing” type. It is possible that the immune response may
be modulated by other factors, as patient’s clinical status. We
did not find a correlation between PBMC-IG and C-reactive
protein, as well as between PBMC-IG and erythrocyte
sedimentation rate. These two clinical tests may not have
correlation with the true inflammatory response that is
occurring.
The positive correlation between weight loss and PBMC-
IG is coherent with other studies that had found correlation
between serum TNF-alpha levels and weight loss. TNF-alpha
and IFN-gamma take part in the Th1 immune response. Bossola
et al. [27] showed that serum TNF-alpha concentrations were
significantly higher in patients with cancer and severe weight
loss when compared with patients having cancer and low
weight loss. Cakir et al. [28] stated that serum TNF-alpha level
and leptin might be responsible for the weight loss in
pulmonary tuberculosis patients. Another study also
correlated chronic administration of TNF-alpha with weight
loss in rats [29].
Another existing knowledge indicates that both TNF-
alpha and IFN-gamma participate in the granuloma formation
and they also appear crucial to the formation of M.
tuberculosis-constraining granuloma. Beyond this effect, IFN-
gamma seems to exert a main role as endogen activator agent
for murine macrophages and their antimycobacterial effects
[30,31]. Other study showed that IFN-gamma actuates
synergistically with TNF-alpha for these antimycobacterial
effects [32].
Our study suggests that true immunological tests as
ELISPOT for PBMC-IG detection must be added to
therapeutical arsenal for patients with TBC. The greater
knowledge about immune response type in infectious diseases
provides new perspectives for treatment of these diseases in
a near future. The predominance of Th1 immune response
induces a greater cellular death by necrosis or apoptosis,
reaching both host and inflammatory cells. We reasoned that
the inhibition of Th1 response for reduction of tissue injury
might be considered in selected cases. We think that the
modulation of the immune response besides of the treatment
of infectious agents will be part of infectious diseases therapy.
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